Sarah Plumridge is a content specialist in the Office of Communications. She writes and takes photos for news stories covering education and alumni affairs, as well as research. She studied biology and studio arts at the University of Rochester and completed her master’s degree in journalism from Northwestern University’s Medill School of Journalism, Media, Integrated Marketing Communications. email@example.com
A phase 1 clinical trial of venetoclax and rituximab combination therapy was shown to be an effective chemo-free treatment option for patients with difficult-to-treat chronic lymphocytic leukemia.